ยินดีต้อนรับกลับมา
เข้าร่วม CoinTime
เข้าสู่ระบบ email
สร้างบัญชี email
ตรวจสอบกล่องจดหมายของคุณ
Lilly Asia Ventures
About
Lilly Asian Ventures is an investment firm that invests in promising life science companies.
- Shanghai,Shanghai,China
- http://www.lillyasiaventures.com
Details
- Industries
- Biotechnology,Pharmaceutical,Venture Capital
- Founded date
- Jan 1, 2008
- Operating Status
- Active
- Also Known As
- 礼来亚洲基金,Lilai Yazhou Jijin
- Investor Type
- Venture Capital
Lilly Asian Ventures makes venture capital investments in Asia for Eli Lilly and Company, a global innovation-driven pharmaceutical company. Lilly Asian Ventures invests in promising life science companies with strong management teams and innovative technology and/or business models. Their initial focus will be primarily on opportunities in China, although they will consider investment opportunities elsewhere in east and south Asia.
Funds Raised
| Announced Date | Fund Name | Money Raised | |
|---|---|---|---|
| Feb 14, 2019 | LAV Biosciences Fund V | $40M | |
| Aug 13, 2017 | LAV Biosciences Fund IV | $450M |
Investments
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Jan 20, 2023
ADARx Pharmaceuticals
|
Series B | $46M | Biotechnology | — |
|
Dec 21, 2022
|
Series B | — | Health Care | — |
|
Dec 9, 2022
|
Series A | $40M | Manufacturing | — |
|
Nov 29, 2022
Rgenta Therapeutics
|
Series A | $52M | Biotechnology | — |
|
Nov 11, 2022
Pulnovo Medical
|
Series Unknown | — | Health Care | — |
Employee Profiles
Exits
Lilly Asia Ventures has had 38 exits. Lilly Asia Ventures most notable exits include Structure Therapeutics , Tmunity Therapeutics
| Date | Company Name | Exit Type | Industry | |
|---|---|---|---|---|
| Feb 2, 2023 | Structure Therapeutics | IPO | Biotechnology | Detail |
| Dec 20, 2022 | Tmunity Therapeutics | M&A | Biotechnology | Detail |
| Jul 24, 2022 | InventisBio | IPO | Biopharma | Detail |
| Apr 1, 2022 | Remegen | IPO | Biotechnology | Detail |
| Mar 29, 2022 | Veritas Genetics | M&A | Biotechnology | Detail |
